Low-Dose Atropine for Treatment of Myopia



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:5 - 12
Updated:4/5/2019
Start Date:June 1, 2018
End Date:October 2022
Contact:Raymond Kraker, MSPH
Email:rkraker@jaeb.org
Phone:813-975-8690

Use our guide to learn which trials are right for you!

Low-Dose Atropine for Treatment of Myopia (Myopia Treatment Study)

Study Objectives

The objectives for this randomized trial are:

1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia
progression over a two-year treatment period in children aged 5 to less than 13 years
(Primary Outcome On-Treatment).

2. To determine the efficacy of atropine treatment on myopia progression 6 months following
cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment).

Synopsis of Study Design The current study is designed as an efficacy study, making effort to
maximize adherence to treatment group assignments. After a run-in phase during which all
participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are
updated if required) to assess their ability to adhere to daily eye drops, participants are
randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off
treatment.

Study Objectives

The objectives for this randomized trial are:

1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia
progression over a two-year treatment period in children aged 5 to less than 13 years
with myopia -1.00 to -6.00D at the time of enrollment (Primary Outcome On-Treatment).

2. To determine the efficacy of atropine treatment on myopia progression 6 months following
cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment).

Synopsis of Study Design The current study is designed as an efficacy study, making effort to
maximize adherence to treatment group assignments. After a run-in phase during which all
participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are
updated if required) to assess their ability to adhere to daily eye drops, participants are
randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off
treatment.

Inclusion Criteria:

- Age 5 years to <13 years at time of enrollment. Children within 4 weeks of their 13th
birthday are not eligible.

- Refractive error meeting the following by cycloplegic autorefraction:

- Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes

- Astigmatism <=1.50D in both eyes

- Anisometropia <1.00D SE

- Gestational age ≥ 32 weeks.

- Birth weight >1500g.

- Parent understands the protocol and is willing to accept randomization to atropine or
placebo.

- Is willing to participate in a 2 to 4 week run-in phase using daily artificial tear
eyedrops.

- Able to return in 2 to 4 weeks for possible randomization.

- Parent has a phone (or access to phone) and is willing to be contacted by
Investigator's site staff.

- Relocation outside of the area of an active PEDIG site within next 32 months is not
anticipated.

Exclusion Criteria:

- Current or previous myopia treatment with atropine, pirenzepine or other
anti-muscarinic agent.

- Current or previous use of bifocals, progressive-addition lenses, or multi-focal
contact lenses.

- Current or previous use of orthoK, rigid gas permeable, or other contact lenses being
used to reduce myopia progression.

- Known atropine allergy.

- Abnormality of the cornea, lens, central retina, iris or ciliary body.

- Current or prior history of manifest strabismus, amblyopia, or nystagmus.

- Prior eyelid, strabismus, intraocular, or refractive surgery.

- Down syndrome or cerebral palsy.

- Females who are pregnant, lactating, or intending to become pregnant within the next
30 months.

- A negative urine pregnancy test will be required for all females who have
experienced menarche.
We found this trial at
14
sites
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Phone: 205-934-6739
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
4901 Calhoun Road
Houston, Texas 77204
Phone: 713-743-1944
?
mi
from
Houston, TX
Click here to add this to my saved trials
Atlanta, Georgia 30322
Phone: 404-778-4725
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
190 East Bannock Street
Boise, Idaho 83712
Phone: 208-381-6910
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boston, Massachusetts 02118
Phone: 617-414-4020
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02453
Phone: 617-355-6401
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60616
Phone: 312-949-7287
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago Ridge, Illinois 60415
Phone: 708-423-4070
?
mi
from
Chicago Ridge, IL
Click here to add this to my saved trials
Columbus, Ohio 43205
Phone: 614-224-6222
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Nashville, Tennessee 37232
Phone: 615-936-2020
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Phone: 405-271-1094
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Poland, Ohio 44514
Phone: 330-746-7691
?
mi
from
Poland, OH
Click here to add this to my saved trials
Portland, Oregon 97239
Phone: 503-494-7830
?
mi
from
Portland, OR
Click here to add this to my saved trials
Salt Lake City, Utah 84107
Principal Investigator: David Petersen, MD
Phone: 801-264-4450
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials